Creating a database for tracking drug-resistant bacterial infections in Switzerland
Development of a Swiss Surveillance Database for Molecular Epidemiology of Hypervirulent and Multi-drug Resistant Pathogens
This study is creating a database to help track drug-resistant bacterial infections in Switzerland, connecting information from hospitals and veterinary labs to improve public health responses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 5 sites (Basel and 4 other locations) |
| Trial ID | NCT04172025 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a shared surveillance database that connects human and veterinary microbiology laboratories in Switzerland. The database will facilitate near real-time molecular epidemiology, allowing for effective tracking of hypervirulent and multidrug-resistant bacterial pathogens. By analyzing previously collected genomic and epidemiological data, the study seeks to enhance outbreak recognition and transmission monitoring across different environments, including humans, animals, and the environment. The focus is on improving public health responses to significant bacterial infections.
Who should consider this trial
Good fit: Ideal candidates include patients with infections or colonizations by multidrug-resistant or virulent bacterial pathogens who have available genomic and epidemiological data.
Not a fit: Patients without infections or colonizations by the specified pathogens or those who decline to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly improve the rapid identification and management of outbreaks caused by drug-resistant pathogens, ultimately reducing morbidity and mortality.
How similar studies have performed: While the approach of creating a shared surveillance database is innovative, similar studies have shown promise in improving outbreak management and pathogen tracking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data * Pathogens included into analysis are: Multidrug-resistant bacteria include: methicillin resistant Staphylococcus aureus (MRSA), Carbapenemase- and/or extended spectrum betalactamase (ESBL)-producing Enterobacteriaceae and non-fermenting bacteria including Pseudomonas aeruginosa and Acinetobacter baumannii, Vancomycin resistant Enterococcus faecium, and others; virulent bacteria include: Neisseria meningitidis, Neisseria gonorrhoeae, Mycobacterium tuberculosis, Campylobacter spp., Salmonella spp., Legionella pneumophila, Listeria monocytogenes, and Streptococcus pneumoniae, and others; Viruses include: Influenza viruses, Measles virus, Enterovirus E68, Respiratory Syncytial Virus and others. Exclusion Criteria: * Decline to sign a general consent or any other declining statement against using data for research purposes.
Where this trial is running
Basel and 4 other locations
- University Hospital Basel — Basel, Switzerland (Recruiting)
- University of Bern — Bern, Switzerland (Recruiting)
- University Hospital Geneva — Geneva, Switzerland (Recruiting)
- University Hospital Lausanne CHUV — Lausanne, Switzerland (Recruiting)
- University of Zurich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Hans Hirsch, Prof. Dr. — Biozentrum, University of Basel
- Study coordinator: Hans Hirsch, Prof. Dr.
- Email: hans.hirsch@unibas.ch
- Phone: +41 61 32 86697
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.